5 Apr 2024
ZERO Biotech, a Hong Kong home grown radiopharmaceutical company, recently had the privilege of meeting with Professor Sun Dong, Secretary for Innovation, Technology and Industry, to discuss the exciting prospects of nuclear medicine development within the region.
During the meeting, the senior management team of ZERO Biotech presented an in-depth overview of the potential of nuclear medicine and its significant impact on healthcare advancements, particularly on cancer treatment. Prof. Sun Dong, known as a renowned professor and scientist in biomedical engineering focusing on medical robotics, expressed that he came across nuclear medicine projects during his tenure at the City University of Hong Kong and is very positive about its application.
Radiopharmaceuticals combine the use of targeting molecules as tracer and radioactive isotopes to diagnose and treat various diseases, including cancer, cardiovascular conditions, and neurological disorders. In cancer treatment, it is believed to be one of the 3 pillars in the future, as described by the CEO of Novartis. It offers precise treatment options, with high efficacy and enhances cancer patients’ quality of life.
"We are thrilled to have had the opportunity to meet with Prof. Sun Dong and discuss the immense potential nuclear medicine holds for Hong Kong," stated Clement Tam, CEO of ZERO Biotech. "With our expertise in radiopharmaceutical development and R&D, we are confident in our ability to contribute significantly to the advancement of biotechnology ecosystem development in our city."
The meeting emphasized the need for collaboration between the government, research institutions, and private enterprises to create a supportive ecosystem for nuclear medicine development. Prof. Sun Dong joined the meeting with his colleagues from the Innovation and Technology Commission, with an aim to guide us through the role of HKSAR and different research funding programmes supporting the development in this critical area.
ZERO Biotech's dedication to innovation and its strong track record in radiopharmaceutical development have positioned the company as a key player in the nuclear medicine field in Hong Kong. By establishing strategic alliances with leading international institutions and leveraging Hong Kong's unique position, ZERO Biotech aims to drive advancements in nuclear medicine that will benefit patients not only locally but also regionally and globally, and aspires to become one of the leading players in Asia.